Agilent Technologies, Inc. (NYSE: A) has announced that it has completed the acquisition of Advanced Analytical Technologies, Inc. (AATI), a provider of capillary electrophoresis-based (CE) solutions for fully automated analysis of a range of molecules for USD 250 million in cash, the company said.
This acquisition brings together two innovators in the electrophoresis space. Advances in genomics, metabolomics, and proteomics are driving growth and demand for robust, purpose built solutions to analyze biomolecules such as nucleic acids (RNA and DNA), proteins, carbohydrates and small molecules.
AATI has developed compelling products based on CE technologies that provide key advances in sensitivity and resolution to address a wide range of applications across a variety of industry segments.
AATI´s 109 employees with join Agilent as part of the new Biomolecular Analysis Division within its Diagnostics and Genomics Group. The new Biomolecular Analysis Division will also consist of Agilent´s existing microfluidics business, which was previously part of Agilent´s Life Sciences and Applied Markets Group.
Agilent Technologies is a global provider of life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers´ most challenging questions. The company generated revenues of USD 4.47 billion in fiscal 2017 and employs 14,200 people worldwide. Information about Agilent is available at www.agilent.com.